Irinotecan‐based regimens vs irinotecan
Severe adverse effects · people with metastatic CRC
Irinotecan‐based regimens showed no clear difference in severe adverse effects compared with irinotecan (moderate certainty).
1 finding from 1 review
- Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes onlyRR 1.18 [0.96, 1.45]6 studies · 2510 participantsModerate